Evidence map›Paper›PMID 39970850›Full record

ArticleJournal of neuroimmunology2025

Sugar utilization by microglia in Alzheimer's disease.

Kaitlyn M Marino, Daniel C Shippy, Tyler K Ulland

Abstract read
In one paragraph

Article in Journal of neuroimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kaitlyn M MarinoNeuroscience Training Program, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America; Department of Pathology and Laboratory Medicine, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America.
Daniel C ShippyDepartment of Pathology and Laboratory Medicine, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America.
Tyler K UllandNeuroscience Training Program, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America; Department of Pathology and Laboratory Medicine, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, United States of America. Electronic address: tulland@wisc.edu.

Funding

Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2019 to 2026
$34.5M
Gut barrier function in Alzheimer's DiseaseR01AG070973 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, REY, FEDERICO E · 2021 to 2025
$3.9M
ß-hydroxybutyrate inhibition of pathology in Alzheimer's diseaseR01AG083883 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin, Federico E Rey · 2023 to 2026
$3.8M
Sugar Utilization by Microglia in Alzheimer's DiseaseR21AG068652 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ULLAND, TYLER KENT · 2020 to 2020
$426k
NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG070973NIA NIH HHS R01 AG083883NIA NIH HHS R21 AG068652
6 · The paper itself

Abstract

Diabetes is a major risk factor for Alzheimer's disease (AD), yet the effect of specific carbohydrate sources in the diet on AD pathology remains unclear. The primary neuroimmune cell, microglia, undergo a metabolic shift during neuroinflammation associated with AD pathology. We utilized existing gene expression data and identified changes in sugar transporters (increased Slc2a1 (glucose) and decreased Slc2a5 (fructose) expression). To examine gene expression with respect to primary sugar source, N9 cells, a mouse microglia cell line, were cultured in glucose or fructose supplemented media and stimulated with lipopolysaccharide (LPS). RNA-sequencing analyses indicated significant changes between control and sugar supplemented media and several differentially expressed genes between glucose and fructose media. Concurrently, 5XFAD mice received equicaloric diets with specific carbohydrate sources: dextrose or fructose. Regardless of diet, sex, or genotype, all mice developed high blood sugar levels; confocal microscopy analyses indicated similar amyloid plaque burden and microglial response relative to the control diet, but there was a change in the microglial response between dextrose and fructose fed mice. Overall, these data indicate microglia preferentially express sugar transporters and sugar source may influence microglial reactivity in response to plaque pathology.

Indexed as

Alzheimer DiseaseFructoseGlucoseMicrogliaAnimalsCell LineFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicFructoseGlucoseAlzheimer's diseaseFructoseGlucoseMicrogliaSugar metabolism

Identifiers

PMID39970850
PMCPMC11908943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.